Search Results - Alberto D’Angelo

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
    Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma

    Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma by Navid Sobhani, Matteo Pittacolo, Alberto D’Angelo, Giovanni Marchegiani

    Published 2025
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer by Navid Sobhani, Alberto D’Angelo, Matteo Pittacolo, Giandomenico Roviello, Tobias Otto

    Published 2019
    Get full text
    Pré-impressão
    Save to List
    Saved in:
  3. 3
    MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy

    MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy by Maria Grazia Rodriquenz, Giandomenico Roviello, Alberto D’Angelo, Daniele Lavacchi, Franco Roviello, Karol Połom

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Advances in anti-BRAF therapies for lung cancer

    Advances in anti-BRAF therapies for lung cancer by Giandomenico Roviello, Alberto D’Angelo, Marianna Sirico, Matteo Pittacolo, Felipe Umpierre Conter, Navid Sobhani

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

    Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy by Marianna Sirico, Alberto D’Angelo, Caterina Gianni, Chiara Casadei, Filippo Merloni, Ugo De Giorgi

    Published 2023
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

    Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer by Giandomenico Roviello, Alberto D’Angelo, Roberto Petrioli, Franco Roviello, Fabio Cianchi, Stefania Nobili, Enrico Mini, Daniele Lavacchi

    Published 2020
    Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption

    AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption by Navid Sobhani, Praveen Neeli, Alberto D’Angelo, Matteo Pittacolo, Marianna Sirico, Ilaria Camilla Galli, Giandomenico Roviello, Gabriella Nesi

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer

    Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer by Navid Sobhani, Anna Ianza, Alberto D’Angelo, Giandomenico Roviello, Fabiola Giudici, Marina Bortul, Fabrizio Zanconati, Cristina Bottin, Daniele Generali

    Published 2018
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer by Navid Sobhani, Alberto D’Angelo, Matteo Pittacolo, Giandomenico Roviello, Anna Miccoli, Silvia Paola Corona, Ottavia Bernocchi, Daniele Generali, Tobias Otto

    Published 2019
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  10. 10
    Methylene Blue—Current Knowledge, Fluorescent Properties, and Its Future Use

    Methylene Blue—Current Knowledge, Fluorescent Properties, and Its Future Use by Tomasz Cwalinski, Wojciech Połom, Luigi Marano, Giandomenico Roviello, Alberto D’Angelo, Natalia Cwalina, Marcin Matuszewski, Giandomenico Roviello, Janusz Jaśkiewicz, Karol Połom

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies

    Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies by Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:

Search Tools: